Patents by Inventor Brian HOLMBERG
Brian HOLMBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12383601Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.Type: GrantFiled: November 25, 2020Date of Patent: August 12, 2025Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu, Serena De Vita, Glenn Dranoff, Boris Engels, Tony Fleming, Brian Walter Granda, Michael R. Greene, Carla Patricia Guimaraes, Anniesha Hack, Brian Holmberg, Connie Hong, Lu Huang, Olja Kodrasi, Joni Waiee Lam, Hyungwook Lim, Elizabeth Dorothy Pratico, Andrew Price, Akash Sohoni, Andrew Marc Stein, Louise Treanor, Chonghui Zhang, Xu Zhu
-
Patent number: 12275795Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.Type: GrantFiled: September 21, 2022Date of Patent: April 15, 2025Assignee: NOVARTIS AGInventors: Aida Abujoub, John Blankenship, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Haihui Lu
-
Patent number: 11952428Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: GrantFiled: February 17, 2023Date of Patent: April 9, 2024Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Patent number: 11939389Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: GrantFiled: February 17, 2023Date of Patent: March 26, 2024Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20230416390Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: ApplicationFiled: March 16, 2023Publication date: December 28, 2023Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20230295322Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.Type: ApplicationFiled: September 21, 2022Publication date: September 21, 2023Applicant: NOVARTIS AGInventors: Aida ABUJOUB, John BLANKENSHIP, Tony FLEMING, Brian HOLMBERG, Connie HONG, Lu HUANG, Haihui LU
-
Publication number: 20230250179Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: ApplicationFiled: February 17, 2023Publication date: August 10, 2023Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20230242647Abstract: The present invention provides engineered immunoglobulins or fragments thereof and methods for their preparation and uses. The engineered immunoglobulins have been derived from human IgG1 and engineered to confer Fc alpha receptor binding ability. In addition, the engineered IgG1 immunoglobulins or fragments thereof can retain binding to Fc gamma receptors and/or FcRn.Type: ApplicationFiled: April 29, 2021Publication date: August 3, 2023Inventors: John BLANKENSHIP, Justine Celine Patricia GUYOT, Brian HOLMBERG, Sebastien IRIGARAY, Darko SKEGRO
-
Publication number: 20230183368Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: ApplicationFiled: February 17, 2023Publication date: June 15, 2023Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20230167193Abstract: The present invention provides an Fc variant of a parent IgA Fc polypeptide, wherein the Fc variant exhibits altered binding to Fc?Rs, wherein the Fc variant comprises at least one amino acid modification in the Fc region of the parent Fc polypeptide.Type: ApplicationFiled: April 29, 2021Publication date: June 1, 2023Inventors: John BLANKENSHIP, Justine Celine Patricia GUYOT, Brian HOLMBERG, Sebastien IRIGARAY, Darko SKEGRO
-
Patent number: 11608382Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: GrantFiled: June 12, 2019Date of Patent: March 21, 2023Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20220396631Abstract: The present disclosure provides multispecific binding molecules that specifically bind to BCMA, a component of a human T-cell receptor complex and either CD2 or a tumor associated antigen, conjugates comprising the multispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates The disclosure further provides methods of using the multispecific binding molecules to treat disease and disorders associated with expression of BCMA. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.Type: ApplicationFiled: May 19, 2020Publication date: December 15, 2022Inventors: Brian Walter Granda, John Blankenship, Aida Abujoub, Tony Fleming, Lu Huang, Connie Hong, Brian Holmberg, Haihui Lu
-
Publication number: 20220364055Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.Type: ApplicationFiled: August 30, 2019Publication date: November 17, 2022Inventors: Louise Treanor, Michael R. Greene, Jennifer Brogdon, Boris Engels, Glenn Dranoff, Olja Kodrasi, Hyungwook Lim, Akash Sohoni, Elizabeth Dorothy Pratico, Anniesha Hack, Aida Abujoub, Tony Fleming, Lu Huang, Connie Hong, John Blankenship, Brian Holmberg, Chonghui Zhang, Dexiu Bu, Andrew Price, Xu Zhu, Andrew Stein, Attilio Bondanza
-
Patent number: 11492409Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.Type: GrantFiled: May 30, 2019Date of Patent: November 8, 2022Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Haihui Lu
-
Publication number: 20220332821Abstract: The present disclosure relates to dosing regimens, formulations, and combinations comprising a multispecific antibody having at least binding specificity towards B cell maturation antigen (BCMA) and a T-cell engaging arm; and methods of using such multispecific antibodies in the treatment or prevention of disease, such as, cancer.Type: ApplicationFiled: June 22, 2020Publication date: October 20, 2022Inventors: Kimberly AARDALEN, Aida ABUJOUB, John BLANKENSHIP, Anuradha CONNOR, Mirek DOSTALEK, Tony FLEMING, Brian HOLMBERG, Connie HONG, Lu HUANG, Haihui LU, K. Gary J. VANASSE
-
Publication number: 20210220404Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.Type: ApplicationFiled: November 25, 2020Publication date: July 22, 2021Inventors: Aida Abujoub, John Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu, Serena De Vita, Glenn Dranoff, Boris Engels, Tony Fleming, Brian Walter Granda, Michael R. Greene, Carla Patricia Guimaraes, Anniesha Hack, Brian Holmberg, Connie Hong, Lu Huang, Olja Kodrasi, Joni Waiee Lam, Hyungwook Lim, Elizabeth Dorothy Pratico, Andrew Price, Akash Sohoni, Andrew Marc Stein, Louise Treanor, Chonghui Zhang, Xu Zhu
-
Publication number: 20190382500Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: ApplicationFiled: June 12, 2019Publication date: December 19, 2019Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20190367628Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.Type: ApplicationFiled: May 30, 2019Publication date: December 5, 2019Inventors: Aida ABUJOUB, John BLANKENSHIP, Tony FLEMING, Brian HOLMBERG, Connie HONG, Lu HUANG, Haihui LU